PaxMedica (PaxMedica) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is PaxMedica Debt-to-Equity?

PaxMedica's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. PaxMedica's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. PaxMedica's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3.39 Mil. PaxMedica's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for PaxMedica's Debt-to-Equity or its related term are showing as below:

PXMD' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.13 Med: 0.73 Max: 1.6
Current: 0.47

During the past 6 years, the highest Debt-to-Equity Ratio of PaxMedica was 1.60. The lowest was -0.13. And the median was 0.73.

PXMD's Debt-to-Equity is ranked worse than
74.07% of 1076 companies
in the Biotechnology industry
Industry Median: 0.15 vs PXMD: 0.47

PaxMedica Debt-to-Equity Historical Data

The historical data trend for PaxMedica's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PaxMedica Debt-to-Equity Chart

PaxMedica Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.13

1.60

PaxMedica Quarterly Data
	Dec18	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.60	0.61	0.74	-2.94	-

Competitive Comparison of PaxMedica's Debt-to-Equity

For the Biotechnology subindustry, PaxMedica's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PaxMedica's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PaxMedica's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where PaxMedica's Debt-to-Equity falls into.

PaxMedica Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

PaxMedica's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.385
	=	0.00

PaxMedica's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.385
	=	0.00

PaxMedica (OTCPK:PXMD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

PaxMedica Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of PaxMedica's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

PaxMedica (PaxMedica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PaxMedica Inc (OTCPK:PXMD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591

Website

https://www.paxmedica.com

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

Executives

Zachary Rome	director, officer: Chief Operating Officer	C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Derby	director, officer: Executive Chairman	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Howard J. Weisman	director, officer: Chief Executive Officer	C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Karen Larochelle	director	900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
John F Coelho	director	22 BENEDICT CRESCENT, BASKING RIDGE NJ 07920
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
David W. Hough	officer: Chief Medical Officer	C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Tardimed Sciences Llc	10 percent owner	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Stephen Sheldon	officer: Chief Financial Officer	2 REVOLUTIONARY WAY, #312, HOPKINTON MA 01748